- Conditions
- Pain
- Interventions
- Zipsor®
- Drug
- Lead sponsor
- Depomed
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Sheffield, Alabama • Stanford, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–21
of 21
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Parkinson Disease
- Interventions
- Transcranial Magnetic Stimulation, Lee Silverman Voice Treatment
- Other · Behavioral
- Lead sponsor
- Le Bonheur Children's Hospital
- Other
- Eligibility
- 45 Years to 80 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Migraine
- Interventions
- Remote Electrical Neuromodulation (REN)
- Device
- Lead sponsor
- Theranica
- Industry
- Eligibility
- Not listed
- Enrollment
- 12,151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Severe Open Fractures of the Tibia (Shin) Bone
- Interventions
- Surgery with an external ring fixator, Definitive fixation with a locked IM nail or plate
- Procedure
- Lead sponsor
- Major Extremity Trauma Research Consortium
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 442 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 27 more
- Conditions
- Epilepsy
- Interventions
- Divalproex Sodium Extended-release 250mg, DEPAKOTE 250mg
- Drug
- Lead sponsor
- Vince & Associates Clinical Research, Inc.
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Bioequivalence
- Interventions
- Treatment A: Acalabrutinib tablet, Treatment B: Acalabrutinib capsule
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 3
- States / cities
- Glendale, California • Brooklyn, Maryland • Salt Lake City, Utah
- Conditions
- Behavior and Mental Disorders, Methamphetamine Disorders
- Interventions
- Adolescent Methamphetamine Treament (AMT), Functional Family Therapy (FFT)
- Behavioral
- Lead sponsor
- Oregon Research Institute
- Other
- Eligibility
- 15 Years to 19 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Obstetric Labour, Premature
- Interventions
- GSK221149 750 mg, Ketoconazole, GSK221149 100 mg, GSK221149 750 mg Fasted, GSK221149 750 mg + Food
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Aortic Aneurysm
- Interventions
- EndoAnchor™, endovascular treament
- Device · Procedure
- Lead sponsor
- Medtronic Cardiovascular
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,090 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more
- Conditions
- Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Pemigatinib, Computed Tomography (CT), Magnetic Resonance Imaging, Optical Coherence Tomography, Bone Scan, Ophthalmoscopy
- Drug · Procedure
- Lead sponsor
- Sameek Roychowdhury
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 109
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 106 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Sofosbuvir, Ledipasvir, GS-9669, GS-9451
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent T-Cell Prolymphocytic Leukemia, Refractory Acute Biphenotypic Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory T-Cell Prolymphocytic Leukemia
- Interventions
- Cytarabine, Fludarabine, Pegcrisantaspase
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Urinary Bladder, Overactive
- Interventions
- Treament, Sham Control
- Device
- Lead sponsor
- FemPulse Corporation
- Industry
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 2
- States / cities
- Woodbury, Minnesota • Seattle, Washington
- Conditions
- Dialysis Amyloidosis
- Interventions
- Lixelle® treatment
- Device
- Lead sponsor
- Kaneka Medical America LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- SLC13A5 Citrate Transporter Disorder
- Interventions
- TSHA-105
- Drug
- Lead sponsor
- TESS Research Foundation
- Other
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Asthma
- Interventions
- Fluticasone propionate 100mcg, Placebo, Vilanterol
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 5 Years to 11 Years
- Enrollment
- 463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 31 more
- Conditions
- Thoracic Aortic Aneurysms, Thoracic Transections, Intramural Hematoma, Pseudoaneurysm, Thoracic Aortic Dissection
- Interventions
- Endoluminal treament of thoracic lesions
- Device
- Lead sponsor
- Rodney A. White, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2021
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Lymphoproliferative Disorder, HHV-8, Malignancy, HIV
- Interventions
- Etoposide, Interferon-alpha, Rituximab, Zidovudine, Liposomal Doxorubicin, Bortezomib, Valganciclovir, Doxorubicin, Vincristine, Cyclophosphamide, Filgrastim (G-CSF), Prednisone, Sirolimus, Observation Only
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prurigo Nodularis
- Interventions
- CC-10004
- Drug
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Metastatic Cancer
- Interventions
- interleukin-12 gene
- Biological
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Chronic Physical Health Conditions
- Interventions
- Self-management group workshops
- Behavioral
- Lead sponsor
- Liberty Mutual Research Institute for Safety
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 4
- States / cities
- Worcester, Massachusetts • Hanover, New Hampshire • Providence, Rhode Island